B-cell Acute Lymphoblastic Leukemia
Conditions
Keywords
B-cell acute lymphoblastic leukemia, Children, Adolescent, Young adults
Brief summary
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).
Detailed description
This is a phase 1, single-center, non-randomized, open-label, dose-escalation study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of fresh, donor-derived, CD19-directed-second-generation CAR T cells (alloCART) in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL) occurring either after allogeneic hematopoietic stem cell transplantation (alloHSCT) or before alloHSCT, in case of refractory disease and availability of a HLA-fully matched donor.
Interventions
DRUGCD19-CAR_Lenti_ALLO
Biological/Vaccine: CD19-CAR\_Lenti\_ALLO A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0
Sponsors
Bambino Gesù Hospital and Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
Patient Inclusion Criteria: 1. Patients with a diagnosis of CD19 expressing B ALL relapse, and one of the following: 1. Relapse after alloHSCT OR 2. Relapsed/refractory disease, with failure of frontline therapy and at least 2 rescue strategies, including CD19/CD22-directed monoclonal antibody and availability of a fully matched related donor. 2. CD19+ count ≥ 50 cells/mcl and/or Minimal Residual Disease (MRD) ≥ 10\^-4. 3. Voluntary informed consent. For subjects \< 18-years old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate. 4. Clinical performance status: patients \> 16 years of age: Karnofsky greater than or equal to 60%; patients ≤ 16 years of age: Lansky score than or equal to 60%. 5. Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the lymphodepletion regimen. 6. Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus. Patients
Exclusion criteria
1. Pregnant or lactating women. 2. Severe, uncontrolled active intercurrent infections. 3. HIV, or active HCV and/or HBV infection. 4. Life-expectancy \< 6 weeks or rapidly progressive disease that in the evaluation of the investigator would compromise ability to complete study therapy. 5. Hepatic function: inadequate liver function defined as total bilirubin \> 4x upper limit of normal (ULN) or transaminase (ALT and AST) \> 6x ULN. 6. Renal function: serum creatinine \>3x ULN for age. 7. Blood oxygen saturation \< 90%. 8. Cardiac function: left ventricular ejection fraction lower than 45% by ECHO. 9. Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject. 10. Presence of active, grade 2-4 acute or chronic Graf versus Host Disease (GvHD) requiring steroid therapy or other immune-suppressive treatment. 11. Relapse occurring before 60 days after alloHSCT. 12. Concurrent or recent prior therapies, before infusion: i. systemic steroids (at a dose of ≥ 2 mg/kg prednisone) in the 2 weeks before infusion of CD19-CAR\_Lenti\_ALLO cells . Recent or recurrent use of inhaled/topical/non-absorbable steroids is not exclusionary. ii. systemic chemotherapy in the 2 weeks preceding infusion of CD19-CAR\_Lenti\_ALLO cells . iii. anti-thymocyte globulin (ATG) or Alemtuzumab (Campath®)in the 8 weeks preceding infusion of CD19-CAR\_Lenti\_ALLO cells . iv. immuno-suppressive agentis in the 2 weeks preceding infusion of CD19-CAR\_Lenti\_ALLO cells v. radiation therapy must have been completed at least 2 weeks before infusion of CD19-CAR\_Lenti\_ALLO cells . vi. other anti-neoplastic investigational agents currently administered or within 30 days prior to infusion of CD19-CAR\_Lenti\_ALLO cells (i.e, start of protocol therapy). vii. Exceptions: 1. there is no time restrictions in regards to intrathecal chemotherapy, but there must be a complete recovery from any acute toxic effects from such treatment. 2. subjects receiving steroid therapy at physiologic replacement doses only are allowed provided that there has been no increase for at least 2 weeks to starting apheresis. Donor Eligibility Criteria Conventional criteria for the eligibility of allogeneic donors will be adopted for the evaluation of cell donors, before apheresis, as required by law.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and establishment of Dose limited Toxicity (DLT) of the infusion of CD19-CAR_Lenti_ALLO cells in pediatric and young adults patients affected by relapsed/refractory BCP-ALL in each dose level | 28 days | DLT is defined as any of the following events: (1) Grade III-IV GvHD refractory to first and second line treatment and chronic GvHD refractory to first and second-ine treatment; (2) any grade 4 non-hematologic toxicity; (3) grade 4 reactions realted to anti-alloCART infusion; (4) death related to alloCART infusion. The Maximum Tolerated Dose/Recommended Dose (MTD/RD) of CD19-CAR\_Lenti\_ALLO to be evaluated for efficacy in the phase II extension will be defined as the highest dose level at which \<33% of patients (no more than 1 out of 6) experience DLT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To estimate the severity of acute GvHD (according to the MAGIC criteria) | 1 year | The severity of acute GvHD will be recorded for every patient |
| To estimate the rate of occurrence of chronic GvHD | 1 year | The occurrence of chronic GvHD will be recorded for every patient |
| To estimate the severity of chronic GvHD (according to the NIH 2014 criteria) | 1 year | The severity of chronic GvHD will be recorded for every patient |
| To estimate the rate of occurrence of acute GvHD | 1 year | The occurrence of acute GvHD will be recorded for every patient |
| Complete Response (CR) or Complete Response with incomplete blood count recovery (CRi) and MRD negativity achievement. | 28 days | To evaluate the proportion of patients achieving CR o CR with incomplete blood count recovery (CRi) and MRD negativity by either flow-cytometry or qPCR at day 28 (defined as a value \< 1x10\^-4) |
| Probability of CR with MRD negativity achievement according to disease burden at time of enrollment. | 28 days | To estimate the probability of obtaining CR with MRD negativity stratified according to the disease at time of enrollment (high disease burden being defined as \> 5% bone marrow lymphoblasts, any peripheral blood lymphoblasts, Central Nervous System (CNS) 3 status, or non-CNS Extra-Medullary (EM) site of disease. |
| To assess Overll Survival (OS) in the whole populations of patients. | 1 year | Overall survival of every patient will be evaluated during follow-up |
| To confirm the safety of the approach at the MTD/RD dose | 28 days | Toxicity of CD19-CAR\_Lenti\_ALLO cells will be recorded for every patient |
Countries
Italy
Contacts
Primary ContactFranco Locatelli, MD, PhD
Backup ContactFrancesca del Bufalo, MD, PhD
Outcome results
None listed